ClinicalTrials.gg

Program

HRS-7058

A development code. Also written as “HRS-7058 capsule/ HRS-7058 tablet”, “Adebrelimab Injection combined with HRS-7058 Capsule” and “HRS-7058 + SHR-1316”.

In Jiangsu HengRui Medicine's pipeline, KRAS G12C. Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Pancreatic Neoplasms, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since May 15, 20266 company-led studies, 6 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine66 open or runningphase 3since May 15, 2026Apr 19, 2024Dec 2026phase 2 · NCT06915142
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-7058, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 19, 2024First study: phase 1 study in Advanced Malignant TumourFirst studyNCT06383871 · 233 planned · China
  2. Apr 1, 2025Phase 2 study in Advanced Malignant TumourNCT06915142 · 300 planned · China
  3. Jun 13, 2025Phase 2 study in Solid TumorsNCT07032077 · 100 planned · China
  4. May 9, 2026Phase 2 study in Pancreatic NeoplasmsNCT07589569 · 92 planned · China
  5. May 15, 2026Phase 3 study in KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard TreatmentPhase 3 reachedNCT07601048 · 450 planned · China
  6. Jul 10, 2026Phase 2 study in Resectable Non-small Cell Lung CancerNCT07704645 · 180 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Advanced Malignant TumourNCT06915142
  2. Jun 2027Primary completion: phase 2 study in Solid TumorsNCT07032077
  3. May 2028Primary completion: phase 3 study in KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard TreatmentNCT07601048
  4. Jun 2028Primary completion: phase 2 study in Resectable Non-small Cell Lung CancerNCT07704645

TargetBeta

“KRAS G12C”the company's pipeline, read by Claude · source
“This is a multicenter, open-label, single-arm, phase II cilinical trial designed to evaluate the efficacy and safety of the KRAS G12C selective inhibitor HRS-7058 in patients with KRAS G12C-mutated advanced pancreatic cancer who had failed 1-2 lines of previous systemic therapy.”study summary, read by Claude · the study

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
opnurasibruleNovartisphase 35

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07704645Resectable Non-small Cell Lung Cancer · China2Not yet recruitingJun 2028180
NCT07601048KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment · China3Not yet recruitingMay 2028450
NCT07589569Pancreatic Neoplasms · China2RecruitingDec 202892
NCT07032077Solid Tumors · China2RecruitingJun 2027100
NCT06915142Advanced Malignant Tumour · China2RecruitingDec 2026300
NCT06383871Advanced Malignant Tumour · China1RecruitingJun 2026233

How it is read

Names in the registry

  • “HRS-7058”, 3 entries
  • “HRS-7058 capsule/ HRS-7058 tablet”, 2 entries
  • “Adebrelimab Injection combined with HRS-7058 Capsule”, 1 entry
  • “HRS-7058 + SHR-1316”, 1 entry
  • “HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy”, 1 entry

Codes read as this program: HRS7058.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.